Back to search

University of York

Quantitative Assessment of the outcome of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Macular Degeneration

Abstract

dc:description.abstract

Neovascular Macular Degeneration is a significant cause of blindness world–wide. Anti-Vascular Endothelial Growth Factor medication injected directly into the eye has halved the disease burden in recent years. Being able to adequately quantify the outcome of neovascular AMD treatment gives perspective not only on appropriate intervention for individual patients, but also the understanding of the science behind the disease, its therapeutics and design of future clinical trials. Assessment tools can be either subjective or objective, and often interrogate either efficacy or safety endpoints. Although patient reported Quality of Life utilities give the ultimate assessment of treatment success for an individual, surrogate biomarkers are more effective in judging short-term response. Visual acuity assessment is useful in analyzing cohorts of individuals, but its subjective nature means that it is not particularly useful in determining individual retreatment decisions. An objective morphological assessment of the macular architecture does provide a good way of assessing short-term response however. Retinal sensitivity also demonstrates usefulness as an endpoint for clinical trials, but as of yet is too cumbersome a technique for high volume clinical work. Functional imaging of the visual cortex remains a research tool at present, but provides promise as a new objective endpoint. Importantly this thesis has confirmed that that cortex is able to regain function after a short period of compromise due to neovascular macular degeneration. Measurement tools to assess the outcome of treatment are best selected, often in composite, with regards to the prime reason for assessment being undertaken.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of York
Year dc:date.issued
2015

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Gale, Richard
Advisor dc:contributor.advisor
  • Anthony, Morland

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.675097

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Gale, Richard. Quantitative Assessment of the outcome of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Macular Degeneration. doctoral thesis, University of York, 2015.